well, with her youngest child developing of symptoms of an inflammatory polyarthritis aged four years old. He went on to have a genetic testing for a mutation in the NOD2 gene which led to a diagnosis of Blau syndrome. Following her sons diagnosis of Blau syndrome this patient's original diagnosis of SJIA was revisited. Blausyndromeis anautosomaldominant auto-inflammatory condition characterised bytheclinical triadofarthritis, recurrent uveitis and granulomatous skin dermatitis; the absence of symptoms in the son's father therefore raised the suspicion that our patient had been misdiagnosed. NOD2 is the gene which has been implicated with 22 recorded mutations. NOD2 codes for a receptor involved in bacterial recognition and immune response. Of note, Blau syndrome shares an identical clinical phenotype with early onset sarcoidosis (EOS); these were initially felt to represent different disease entities but the advent of genetic testing has demonstrated that in fact they are the same disease. Some refer to Blau syndrome as the inherited form of the disease and EOS the sporadic form. Given our patient has no family history of inflammatory arthritis it is likely she has a sporadic mutation. Our patient underwent genetic testing, confirming that she had the same mutation as her son and thus supporting a change in her diagnosis. We prefer the terminology of Blau syndrome as an overarching diagnosis for our patient and her son, rather than EOS and Blaurespectively, as it clearly communicates the presence of a rare, genetically predetermined, paediatric polyarthritis. Discussion: Like the far more prevalent SJIA, Blau syndrome is a paediatric polyarthritiswithsystemic manifestations. Despite this overlap there are key differences that have been identified between the two with respect to both clinical findings and treatment strategies. Prevalence of uveitis in patients with Blau syndrome has been estimated to be 81%; this is far rarer in SJIA with only 0.6% of patients affected. Additionally in SJIA the posterior segment involvement, typified by choroidal scars, is never seen whereas it is found in 72% of Blau uveitis. Furthermore, uveitis in Blausyndrome is more likely to bebilateralthan JIA and morelikely to confer complications such as cataracts and visual impairment. Arthritis in Blau syndrome shows a symmetrical pattern involving both large and small joints. Classically florid, synovitis is exhibited at the joints with tenosynovitis and cysts frequently seen. Flexion deformities in the hands such as campylodactyly are common. Radiologically changes in Blau syndrome classically show no evidence of erosions. This contrasts with our patient whose radiographs have displayed progressive erosive damage; this discrepancy is explained by our patient having a rarer erosive form of Blau syndrome. There is no consensus regarding treatment for patients withBlausyndrome; theevidencesuggeststhatinflammationinBlausyndrome may persist despite combination use of steroids, immunosuppressive drugs and biologics. TNF alpha inhibition and IL-1 blockade, such as those received by our patient, have been seen anecdotally to partially control articular and ocular inflammation respectively. It seems therefore that our patient has been treated appropriately within the current body of evidence that is available, although establishing the diagnosis clearly has importance regarding disease phenotype. Critically had the patients true diagnosis been known, preconception planning with her would have included offering referral for genetic counselling to discuss the implications of having Blausyndrome. Key Learning Points: Blau syndrome is commonly misdiagnosed as SJIA. Consider the alternative diagnosis of Blau syndrome in patients displaying an autosomal dominant inheritance pattern of SJIA. Posterior segment uveitis is not seen in SJIA; its presence should prompt consideration of an alternative diagnosis. Although uncommon, joint erosions on radiology do not preclude a diagnosis of Blau syndrome. Genetic counselling services should be offered topatients with Blau syndrome. Introduction: Immunoglobulin G4-related disease (IgG4-RD) represents an immune-mediated fibro-inflammatory condition resulting in mass forming lesions with characteristic histopathological appearances. The disease can affect multiple different organs, with a range of clinical presentations to different medical and surgical specialties. Case description: We describe a case of a 71-year old female who presented with refractory facial pain following a dental procedure. She was treatedwithrepeated coursesofantibiotics bythedentistand wassubsequently referred for an ENT opinion. A CT scan revealed complete opacification of the left maxillary sinus with bony erosion of the floor, medial, anterior and posterior aspects of the maxillary antrum. Histological biopsies were reported as showing eosinophilic angiocentric fibrosis with an IgG4:IgG ratio of > 40%, consistent with a diagnosis of IgG4-RD. Peripheral blood IgG4 levels were normal and extended autoantibody screening, including ANCA, viral and TB screening were negative. Past medical history was significant for an unexplained episode of bronchus intermedius stenosis, ten years earlier. Thoracotomy yielded multiple biopsies which were reported at the time as showing non-specific granulomatous inflammation. Analysis of the historic samples revealed elevated levels of IgG4 staining. The patient was referred to rheumatology and commenced prednisolone 30mg orally with some improvement in facial pain. The dose was subsequently weaned to a maintenance dose of 7.5mg daily. Mycophenolate mofetil (MMF) was commenced as a steroid sparing agent (1 gram twice daily). Unfortunately, there was radiological evidence of disease progression with ongoing bone loss, despite this therapy and the decision was made in the IgG4-RD MDT, to proceed with Rituximabwithcyclophosphamide induction. Therehasbeensome resolution of the inflammatory changes and treatment is ongoing. Discussion: With an estimated incidence of 60m per million populations, IgG4-RD isarare, butincreasinglyrecognized condition.First linetherapy remains glucocorticoids. Rituximab has been commissioned by NHS Englandforuseinrefractoryororgan threatening IgG4-RD. Inthiscase rituximab has shown superiority to MMF in improving the symptoms and resolution of inflammation. Arguably the trial of MMF delayed the more effective treatment and resulted in more bony loss. The extent to which the addition of iv cyclophosphamide potentiated the effects Rituximab is not known and more research is needed. The episode of bronchus intermedius stenosis suffered almost a decade earlier, coupled with the multiple courses of antibiotics and delayed contemporary diagnosis, highlights the diagnostic challenges of IgG4-RD. Key Learning Points: Consider further review and IgG4 staining of any available previous histopathology samples if a diagnosis of IgG4-RD is made. Consider the addition of cyclophosphamide in organ threatening disease as an induction agent. Consider Rituximab early in organ threatening disease to preventprogression to irreversible damage. Disclosure: F.Osman: None. J.Vila: None. Rheumatologists frequently manage patients with multisystem diseases. It is not uncommon for the diagnosis to be unclear initially, but in most cases the combination of clinical features, the course of the disease and targeted investigation confirms a diagnosis; allowing delivery of evidence-based treatments. However, there are some cases that donot fit arecognised disease pattern and inwhomextensive investigation may not identify a unifying diagnosis. We describe the complex case of a 28 year old female who initially presented in 2011 with symptoms related to a pleural effusion and who has since developed an increasing number of manifestations of an as yet undiagnosed multi-system inflammatory disorder. Consequently, she has been seen by numerous specialties and had extensive investigation undertaken throughout the years. She has also had trials of different immune modulating treatments with little effect. She has remained a diagnostic challenge and involvement of tertiary centres has been necessary. This case highlights the unusual clinical course of this illness, the various investigations and trials of therapy, and the many cross-site and inter-specialty discussions we have had regarding this patient. We hope this case highlights a rare clinical entity that may allow a discussion at conference to improve care of this patient and other patients with similar presentations. Case description: We present the case of LF, a 28 year old female with a past medical history of autism/Asperger's syndrome, bilateral sensorineural deafness, migraines. She has one relative with rheumatoid arthritis (mother) but no other significant family history. She initially presented in November 2011 at 22 years old with breathlessness, pleuritic chest pain and a large right pleural effusion. Empyema was suspected and she was treated with antibiotics and a chest drain. Sampling revealed an exudative effusion and microbiology was negative. At the time of chest drain insertion the pleura was notably thickened. She was allowed home but represented in March 2012 with bilateral pleural effusions. An echo excluded heart failure, and she was again treated with antibiotics and discharged. Following these initial admissions she has had recurrent presentations with problems arising from different organ systems and has had involvement from rheumatology, respiratory, gastroenterology, dermatology, infectious diseases, ophthalmology, genetics and neurology. repeat upper and lower GI endoscopy showed ileitis but no granuloma and the question of Crohn's disease was raised again. May 2018: seen in tertiary centre and case discussed with auto-inflammatory disease and interferonopathy specialists in Edinburgh and USA She has been extensively investigated through the years. The following summarises her testing: CRP usually 20-40 mg/L and ESR 25 mm/hr, Urine for 5HIAA and catecholamines negative, ferritin 33 ng/ml microbiology: Pleural and ascitic fluid repeatedly negative onmicrobiologyculture, sputum,faeces, pleural fluid, ascitic fluid, broncho-alveolar lavage, pleural biopsy and peritoneal biopsy all negative on testing for AAFB, HIV, Hepatitis B and Hepatitis C negative, syphilis antibody negative, filarial ELISA, brucella IgG and IgM, leishmania, schistosomal ELISA, strongyloides ELISA, toxoplasma all negative. Pro-calcitonin 0.05 ng/ml. Immunology: repeated auto-antibody testing -negative RF, anti-CCP, ANCA, C3, C4. ANA 1:160,ENAnegative,serumACEnormal,C1inhibitornormal,lymphocyte subsets generally reduced, normal levels of CH100 and AP100 (classical and alternative complement pathways), IgG, IgA and IgM raised. Genetic testing: HLA B27 negative, Array CHG shows deletion of chromosome 15 and duplication of NLGN4 gene on X chromosome. Cardiorespiratory: Thoracoscopy showing inflammatory lesions on the diaphragm with thickened and inflamed pleura. Pleural biopsy showed severe inflammation with lympho-plasmacytic infiltrate and reactive surface mesothelium. PFTs showing progressive restrictive defect (FVC 26% predicted, FEV1 24% predicted). Repeated chest CT showing progressive bilateral consolidative foci and pleural effusions. Organising pneumonia demonstrated recently. Bronchoscopy with BAL negative for microbiology and AAFB testing, six minute walk test showing desaturation on walking, repeated echocardiograms showing normal LV and RV function. GI: barium swallow showed oesophageal stricture, repeated upper GI endoscopies showing hiatus hernia and oesophagitis, repeated colonoscopy initially showing apthous ulcers and later ileitis, faecal calprotectin positive (480 ug/g at highest), MRI not tolerated but CT small bowel showed gross ascites and extensive nodular peritoneal enhancement. Diagnostic laparotomy showing pus like ascitic fluid negative on microbiology and AAFB culture. Other Imaging: DEXA showed osteoporosis, MRI head and inner ear to look for inflammation of inner ear structures negative. Hand x-rays, MRI both hips and L knee showed no features of inflammatory arthritis. Pathology: peritoneal biopsy showed a granulomatous inflammatory infiltrate containing granulomas with central necrosis but mycobacteria stains were negative, pleural biopsy showed severe inflammation with lympho-plasmacytic infiltrate and reactive surface mesothelium. Staining of rectal biopsy for amyloid negative and no excessive staining of IgG or IgG4. Over the years she has had trials with a number of different treatments as described below: pused on and off with a variable response. At one stage she became significantly cushingoid with this and recent DEXA has shown osteoporosis hydroxychloroquine used with some response from September 2012 but stopped during admission in March 2013 with a worsening pleural effusion. Switched to azathioprine as a steroid sparing agent in May 2013 but not tolerated. Methotrexate started June 2013 again for steroid sparing but ineffective so discontinued. August 2014: brief trial of colchicine. OctoberDecember 2014 stopped due to diarrhea. Empirical TB treatment with rifater (rifampacin, isoniazid, pyrazinamide), ethambutol and pyridoxine in September 2016 for nine months. Current thinking is that she has an auto-inflammatory condition or an interferonopathy, although the presentation is atypical for the known single gene mutation autoinflammatory diseases. The current plan for her management is a trial of anti-IL1 therapy, and in the event of failure of this, aJAK inhibitor. Discussion: This case highlights the challenges associated with managing rare diseases. The multisystem nature and the fluctuating course of this patients's illness led to her being seen by multiple different medical specialties and each had a different approach to further investigation or management. To our knowledge, this is a unique case in terms of the manifestations of the systemic disorder and the lack of identified mutation seen in recognised auto-inflammatory conditions. In managing this complex case, whilst attempting a series of treatments, our approach has also involved attempts to coordinate efforts with colleagues in other specialties and to seek assistance from national experts to see if we can come up with a more satisfactory management plan. Our patient has displayed a variable response to steroid therapy. She has had multiple courses of antimicrobials, despite no definitive evidence of infection. She has also had no response to methotrexate, colchicine or hydroxyxhloroquine. Her lung disease has progressed to the extent that she may be considered for lung transplant. There remains uncertainty in considering the best way forward in terms of pharmacological management. Anti-IL1 therapies have a role in treatment of auto-inflammatory conditions, with reports of success. Many respond to steroid therapy, some respond to colchicine, and some respond to DMARD therapies such as methotrexate. The inability of intial genetic testing to identify a known associated mutation has hindered diagnosis and management. However, the number of recognised mutations is increasing, and it is recognised that a large proportion of cases of auto-inflammatory conditions will not possess a known mutation. Our intention is to embark on IL-1 therapy after awaiting further genetic testing. Another option may bea JAK inhibitor. Key Learning Points: Patients with rare multi-system inflammatory disorders are challenging to manageIt is important to investigate these patients in a targeted manner to try to narrow the differential diagnosisIf condsidering an auto-inflammatory condition, consider genetic analysis, however this may not be conclusiveInter-specialty collaboration is vital. Tertiary referraland/or expert opinion should be sought. We report the case of a patient with relapsing polychondritis who presented with significant tracheal involvement (laryngeal stridor, exertional dyspnoea) partially responsive to initial induction therapy with CS but optimalclinical response with CyC therapy. Casedescription:A46yearoldfemalepresentedwithathreeweekhistory of exertional breathlessness, costochondritis, weight loss, lethargy and arthralgia in her feet. Initial investigation revealed crackles in her chest with tenderness at costochondral junction. Her CRP was raised to 260, ANCA/ ANA/viral screen was negative, pro-BNP was 74, CTPA was normal, blood cultures were negative and echocardiogram did not show any vegetation.
AN UNSOLVED MYSTERY OF MULTISYSTEM DISEASE
Her flow volume loop showed severe airflow obstruction, FVC 2.40 (68% predicted), FEV1/FVC was 36% (45% predicted) with reduced gas transfer. The initial PET-FDG showed tracer activity in all costochondral joints, glotticand supra-glotticregions,and noFDG activityinthe eye,auricularor nasalcartilage.Shewasinitiatedwith60 mgoforal prednisolonealongside PPI and calcium/vitamin D supplement. Unfortunately, she remained symptomatic following initial induction therapy with oral CS with persistent laryngealstridor,breathlessnessandhighCRP.Shewasthencommenced on 500mg of IVMP for three days followed by CyC therapy (15mg/KG-6 cycles). Following this, her CRP improved to 30 but she remained breathless and developed a hoarse voice and nasal deformity. A repeat CT showedongoingdiseaseactivity,thickenedtracheaandairwaynarrowing. She was readmitted four weeks later for 2nd cycle of IVMP and referred for consideration of tracheal stenting. Following the 2nd cycle of IVMP and
